Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-03-09
2010-06-22
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S343000, C514S361000, C514S367000, C514S371000, C514S375000, C514S376000, C514S407000, C544S405000, C546S278700, C548S128000, C548S163000, C548S195000, C548S217000, C548S229000, C548S361100, C548S364100, C548S364400, C548S365700
Reexamination Certificate
active
07741327
ABSTRACT:
Provided herein are compounds of the formula (I):as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.
REFERENCES:
patent: 6528543 (2003-03-01), Bizzarro et al.
patent: 2006/0167053 (2006-07-01), Iino et al.
patent: 2006/0258701 (2006-11-01), Mitsuya et al.
patent: 1 600 442 (2005-11-01), None
patent: WO 00/58293 (2000-10-01), None
patent: WO 01/62726 (2001-08-01), None
patent: WO 01/83465 (2001-11-01), None
patent: WO 01/85706 (2001-11-01), None
patent: WO 01/85707 (2001-11-01), None
patent: WO 02/46173 (2002-06-01), None
patent: WO 03/015774 (2003-02-01), None
patent: WO 03/095438 (2003-11-01), None
patent: WO 2004/050645 (2004-06-01), None
patent: WO 2004/052869 (2004-06-01), None
patent: WO 2004/072031 (2004-08-01), None
patent: WO 2004/072066 (2004-08-01), None
patent: WO 2004/076420 (2004-09-01), None
patent: WO 2004/081001 (2004-09-01), None
patent: WO 2005/080359 (2005-09-01), None
patent: WO 2005/080360 (2005-09-01), None
patent: WO 2005/090332 (2005-09-01), None
patent: WO 2005/095417 (2005-10-01), None
patent: WO 2005/095418 (2005-10-01), None
patent: WO 2005/103021 (2005-11-01), None
patent: WO 2005/121110 (2005-12-01), None
patent: WO 2006/016178 (2006-02-01), None
patent: WO 2006/016194 (2006-02-01), None
patent: WO 2006/040529 (2006-04-01), None
patent: WO 2006/058923 (2006-06-01), None
patent: WO 2006/125972 (2006-11-01), None
patent: WO 2007/007040 (2007-01-01), None
patent: WO 2007/007041 (2007-01-01), None
patent: WO 2007/007042 (2007-01-01), None
patent: WO 2007/007886 (2007-01-01), None
patent: WO 2007/017649 (2007-02-01), None
patent: WO 2007/026761 (2007-03-01), None
patent: WO 2007/041365 (2007-04-01), None
patent: WO 2007/041366 (2007-04-01), None
patent: WO 2007/051845 (2007-05-01), None
patent: WO 2007/051846 (2007-05-01), None
patent: WO 2007/051847 (2007-05-01), None
patent: WO 2007/104034 (2007-09-01), None
patent: WO 2007/122482 (2007-11-01), None
patent: WO 2008/012227 (2008-01-01), None
patent: WO 2008/014311 (2008-01-01), None
patent: WO 2008/132139 (2008-11-01), None
M.C.T. Fyfe, Diabetologia, DOI 10.1007/s00125-007-0646-8.
Berthel Steven Joseph
Brinkman John A
Hayden Stuart
Haynes Nancy-Ellen
Kester Robert Francis
Bianchi Kristin
Hoffmann-La Roche Inc.
Johnston George W.
Megerditchian Samuel H.
Saeed Kamal A
LandOfFree
Pyrrolidinone glucokinase activators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolidinone glucokinase activators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolidinone glucokinase activators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4204961